SCHEMBL248702

SCHEMBL248702

CC1(N)CCCCC1(C)N

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1672601 1.00 TSHR (0.30) TSHRCYP2C19
SCHEMBL1672603 1.00 TSHR (0.30) TSHRCYP2C19
SCHEMBL2489793 1.00 TSHR (0.30) TSHRCYP2C19
SCHEMBL16654228 1.00 TSHR (0.30) TSHRCYP2C19
Hydrochloric Acid SCHEMBL742331 0.96
Hydrochloric Acid SCHEMBL31324651 0.96
SCHEMBL16639232 0.96 TSHR (0.35) TSHRCYP2C19
SCHEMBL18226106 0.92
SCHEMBL29674979 0.92
SCHEMBL31241431 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865859-A Preparation method of enantiomerically pure p-toluenesulfonamide 常州琦诺生物科技有限公司 2024-04-12 CN claimed
CN-117242062-A Process for the preparation of intermediates useful in the synthesis of xanthine oxidase inhibitors 株式会社LG化学 2023-12-15 CN claimed
CN-117024354-B Preparation method of Rui Mi Buti Ni 天津凯莱英制药有限公司 2023-12-08 CN claimed
CN-117203200-A Process for preparing xanthine oxidase inhibitors 株式会社LG化学 2023-12-08 CN claimed
CN-117143010-A Bipyridine diamine ligand and preparation method thereof 山东农业大学 2023-12-01 CN claimed
CN-117024354-A Preparation method of Rui Mi Buti Ni 天津凯莱英制药有限公司 2023-11-10 CN claimed
EP-4211118-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR Cerevance, Inc. (US) 2023-07-19 EP claimed
CN-112250675-B Tyrosine kinase inhibitor containing amide structure and preparation method thereof 深圳市第二人民医院(深圳市转化医学研究院) 2023-06-27 CN claimed
CN-112300138-B Tyrosine kinase inhibitor containing ester group structure and preparation method thereof 深圳市第二人民医院(深圳市转化医学研究院) 2023-06-27 CN claimed
CN-116120219-A Polysubstituted pyrrole compound, preparation method thereof and application thereof in preparation of HBV capsid protein inhibitor 吉斯凯(苏州)制药有限公司 2023-05-16 CN claimed
WO-2006119417-A1 PROCESSES FOR THE PREPARATION OF O-(6-PYRAZOL-1-YL-PYRIDIN-3-YLMETHYL)-HYDROXYLAMINE ENANTA PHARMACEUTICALS, INC. (US) 2006-11-09 WO claimed
CN-1854128-A Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds MASSACHUSETTS INST TECHNOLOGY (US) 2006-11-01 CN claimed
CN-1266112-C Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation MASSACHUSETTS INST TECHNOLOGY (US) 2006-07-26 CN claimed
CN-1684944-A method for copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds MASSACHUSETTS INST TECHNOLOGY (US) 2005-10-19 CN claimed
EP-1534671-A2 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2005-06-01 EP claimed
CN-1518534-A Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation 麻省理工学院 2004-08-04 CN claimed
EP-1390340-A1 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2004-02-25 EP claimed
WO-2004013094-A2 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2004-02-12 WO claimed
US-20030065187-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-04-03 US claimed
WO-2002085838-A1 COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065187-A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds ADH5, CBR3, ALDH3A1 TSHR 3079/4885CYP2C19 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.